Hot News!


Enquirer: No mayor primary? Save $400K

Enquirer: Mayor race set without primary

WCPO: Political Blogger Withdraws From Mayor Race

Tweets!

07-03 1:56
Cincinnati Beacon
The anti-rail charter amendment is NOT about "choices": http://tinyurl.com/mx7l66
07-03 6:15
Cincinnati Beacon
If you need another reason to hate Republicans: http://bit.ly/ZBXyE
07-02 4:33
Cincinnati Beacon
This just in from Chris Monzel: "I am not affliated with COAST."
06-30 5:50
Cincinnati Beacon
Weekly ISO Meeting July 2nd - 7pm on Revolution in Iran in 1979 - 4001 Hamilton Ave in Northside in the IWW Headquarters
06-28 7:09
Cincinnati Beacon
The Dean rocks Newsmakers: http://bit.ly/12ac6k

Visit us at Twitter!





On today's date in The Beacon archives, we published:

City on Hook for F.S. Restaurant (2008)
Bob Kraft, Henry Heimlich’s Spokesperson, Hypes Nazi (2007)
Debunkify Countdown for July 10th (2006)
Sleepwalking to Disaster (2006)

Contact Us

v mail: (513) 685-0678
e mail: click here

Saturday, March 01, 2008


Vic Wulsin:  In Her Own Words

Posted by The Dean of Cincinnati

What is the truth about Vic Wulsin’s involvement in human malariotherapy experiments, which have been compared to Nazi Germany?  If you are predisposed to believe Vic Wulsin, then now is the time to analyze her own words.  The following excerpts are taken from her report to the Heimlich Institute, aptly named “Immunotherapy and Beyond.”  Some of the writing in the report matches Wulsin’s claims about being a critic of the experiments.  Most, however, shows Wulsin writing a business proposal which suggests continued experiments—particularly telling since she now says the concept has no scientific validity.

1.  Wulsin’s own introduction on the report’s first page indicates that she was hired to do more than a “literature review”:

Three months ago I began a consultancy with the Heimlich Institute [HI] for two reasons.  First, I was to evaluate the viability of Malariotherapy Therapy as a focus for HI and to recommend to HI’s Board of Directors the requisite next steps in developing it as a life-enhancing &/or life-prolonging intervention for persons living with HIV/AIDS. Second, I would identify the comparative advantage (“market niche”) of the Heimlich Institute in developing Immunotherapy or any aspect of life-enhancing &/or life-prolonging interventions.

Please notice that she was hired to recommend “requisite next steps in developing” malariotherapy.  Additionally, she said she wanted to “identify the comparative advantage (“market niche”) of the Heimlich Institute.”  When Vic Wulsin said she wrote a “literature review,” she is only telling part of the story.  The report is also a business plan.

2.  In this next excerpt, Wulsin admits to analyzing raw human data from East African subjects:

Secondly, I would conduct independent analyses on available data that had not been published. I have been unable to glean additional data from China, but have obtained raw data from East Africa. Thirdly, I planned to speak to as many of the leaders in the field of Immunotherapy as possible, beginning with HJH and ES, and leading to a site visit of ongoing trials in China and/or East Africa. I have succeeded in speaking directly with several scientists involved with malaria, HIV/AIDS, and/or Immunotherapy, but was unable to speak to key contacts in China and East Africa. The site visits did not materialize due to severed relations (China) and logistical difficulties (East Africa).

When she learned about these human experiments, which had been widely condemned by the time she published this report, she did not report them to appropriate oversight agencies.  Insted, she analyzed data, spoke with people working on the experiments, and she even wanted to take site visits to China and East Africa.  This is one year after the Cincinnati Enquirer published a front page article blasting the China experiments as unethical.

3.  As Wulsin has stated, her report does state that evidence indicates malariotherapy will not cure AIDS.  But this statement cannot be taken out of the larger context of the report, and the other things Wulsin supports:

The preponderance of evidence indicates that neither malaria nor Immunotherapy will cure HIV/AIDS. Few data address clinical changes during and following malaria and Immunotherapy. The data regarding improving indicators of immune status, such as CD4 counts and HIV load, are inconsistent. The original Chinese studies reported a consistent rise in CD4 counts, sustained over a 24-month period. More recent follow-up indicate some CD4 counts rise and others decline. The East African data are similarly erratic. Overall, five counts decline (Patients 1, 2, 3, 6, and 7) and three (Patients 4, 5, and 8) rise [see Table 2]. Furthermore, during the nine-month follow-up period the levels fluctuate: inconsistently but not unexpectedly.

However, shortly after writing that, Wulsin claims that more investigation into East African results is warranted:

Nevertheless, the potential for success of Immunotherapy in making a substantial (both statistically and biologically significant) improvement in the lives of HIV-positive patients, based on the EastAfrican trials, warrants verification and elaboration.

So, despite concluding that evidence shows malariotherapy to be ineffective, Wulsin called for more “verification and elaboration.”  Why would she want to do more work if she found the idea as unsound as she now claims?  What were her motives in calling for further investigations?

4.  Despite what she says, Wulsin wanted to continue engaging in malaria experiments.  In this next excerpt, she calls on subjecting the research protocols to ethical guidelines—but she has not explained why she failed to report the ethical problems with the experiments in the first place; further, if what she says now is true (that the idea has no merit), then why bother making such plans for the future?

Studies of Immunotherapy are ethically justifiable as long as three conditions are met.

1. Patients must be informed of - and understand - the relative costs and benefits to Immunotherapy and its alternatives.
2. Research protocols must be approved by local (operating) and donor (managing) institutional review boards. These authorizations should be readily available for examination by any critics, patients, potential collaborators, or others.
3. Research protocols should be designed prior to operations. “Fishing expeditions” for possible benefits are no longer warranted. Specific outcomes should be investigated. Any deviations from research protocols must be accounted for.

Notice that she says “fishing expeditions” are “no longer warranted.”  She seems to suggest that they were previously acceptable—despite the fact that this work had already been condemned.  When she found it was ongoing, she participated instead of filing a complaint to the appropriate agency.

5.  In section X of her report, Wulsin suggests several ideas for continuing to work on malariotherapy.  Why would she do this, if what she says today is true?

X. Recommendations vis-à-vis Immunotherapy

Brainstorming leads to a host of potential actions the Heimlich Institute could take. These are meant for discussion only. They are not meant to be prescriptive.

Programmatic Next Steps

1. Write a strategic plan for the Heimlich Institute.
2. Rename malariotherapy “Immunotherapy” [“IT”].
3. Verify and elaborate on East Africa Phase II trial.
4. Explore further collaborating with Michele Ashby, the Denver Gold Group, and/or the CEOs, medical directors, &/or others of appropriate mining companies.
5. Complete and publish review of Immunotherapy.

Why would she rename the project if it is medically unsound and unethical?  Why would she verify and elaborate on East African data?  Why would she want to talk with other mining companies, if this idea is one she did not want to support in any way?

In a recent campaign press release, Team Wulsin stated the following:

Dr. Wulsin, as she has maintained all along, did nothing wrong. She was hired by The Heimlich Institute to perform a literature review and was fired when the Institute realized her report opposed further research without proof of effectiveness and significantly upgraded standards of review.

This statement is partially true.  As the first excerpt provided above shows, she was not hired to do just a “literature review.”  And again, the “wrong” of which Wulsin has been accused is in not reporting these experiments to appropriate oversight agencies.  Instead, she analyzed raw human data and wrote a business plan.  Was she really fired from the Heimlich Institute?  Is there any proof that she was fired for writing this report, other than her own claims? 

As the still active complaint against Wulsin’s medical license shows, she has been accused of complicity in the experiments for failing to report them. 


Share This Article!
Listen to this article

Help The Cincinnati Beacon Grow! Participate in Social Networking!

Members



Auto-login on future visits

Show my name in the online users list

Forgot your password?

Register

Tell us what you think!

Anonymous comments are allowed, but you can create an account above to stamp your name and to avoid typing the anti-spam code.

If you are not familiar with our rules for leaving comments, click here! The Cincinnati Beacon is not responsible for the contents of any comments. Comments do not represent the views of the moderators of The Cincinnati Beacon.

Name:

Email:

Location:

URL:

Smileys

Remember my personal information

Notify me of follow-up comments?

Submit the word you see below:




Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 2.5 License.